Phase 3 MSI-H Clinical Trials
4 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–4 of 4 trials
Recruiting
Phase 3
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
MSI-H/dMMR Colorectal CancerResectable Colon Cancer
Akeso386 enrolled1 locationNCT07412613
Recruiting
Phase 3
Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas
Gastric CancerMetastatic CancerAdvanced Cancer+1 more
Centre Leon Berard132 enrolled6 locationsNCT06346197
Recruiting
Phase 3
PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer Patients
Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)
Centre Hospitalier Universitaire Dijon68 enrolled1 locationNCT06762405
Recruiting
Phase 3
A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer
MSI-H
Innovent Biologics (Suzhou) Co. Ltd.360 enrolled1 locationNCT05890742